Mast Cell Activation Syndrome: Improved Identification byCombined Determinations of Serum Tryptase and 24-Hour Urine 11β-Prostaglandin2α

Anupama Ravi, Joseph Butterfield, Catherine R. Weiler

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Mast cell activation syndrome (MCAS) describes patients with episodes of mast cell mediator release, with negative bone marrow biopsy results, and the failure to meet the criteria for systemic mastocytosis. Objective: Identify elevation of mast cell mediators of patients with MCAS. Methods: We performed a retrospective study of 25 patients with MCAS who were evaluated at Mayo Clinic from 2006 to2012. Patients were reviewed for MCAS symptoms and mast cell mediators, including serum tryptase and 24-hour urine N-methyl histamine (N-MH) and 11β-prostaglandin-F (11β-PGF). The study was approved by the institutional review board. Results: Urinary 11β-PGF was the most frequently elevated product in MCAS of our 25-patient cohort. Flushing and pruritus had the greatest correlation with elevation of 24-hour urine 11β-PGF value at baseline. The serum tryptase level was elevated in 10 patients, whereas the N-MH level was elevated with 2 patients. Eight of 9 patients with MCAS and with elevated 24-hour urine 11β-PGF who underwent aspirin therapy and follow-up urinary studies had normalization of this mediator (1patient did not have a follow-up urine study). Six of these 9patients with MCAS who underwent aspirin therapy had symptomatic improvement. Conclusion: We recommend measurement of 24-hour urine 11β-PGF2α and serum tryptase levels of patients with symptoms suggestive of MCAS. Measurement of 24-hour urine 11β-PGF and serum tryptase levels can help avoid misdiagnosis and overinterpretation of MCAS symptoms in clinical practice. Given that an elevation of 24-hour urine N-MH level was found only in 2 patients, measurement of this mediator may be less helpful in diagnosing MCAS. We recommend aspirin therapy for patients with MCAS and with elevated 24-hour urine 11β-PGF levels.

Original languageEnglish (US)
Pages (from-to)775-778
Number of pages4
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume2
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Tryptases
Mast Cells
Urine
Dinoprost
Serum
Histamine
Aspirin
Systemic Mastocytosis
Research Ethics Committees
Pruritus
Diagnostic Errors

Keywords

  • 11β-Prostaglandin-F2α
  • Mast cell
  • Mast cell activation syndrome
  • Tryptase

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Mast Cell Activation Syndrome : Improved Identification byCombined Determinations of Serum Tryptase and 24-Hour Urine 11β-Prostaglandin2α. / Ravi, Anupama; Butterfield, Joseph; Weiler, Catherine R.

In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 2, No. 6, 2014, p. 775-778.

Research output: Contribution to journalArticle

@article{ee72dbe29f614431bb03113bd9995ba5,
title = "Mast Cell Activation Syndrome: Improved Identification byCombined Determinations of Serum Tryptase and 24-Hour Urine 11β-Prostaglandin2α",
abstract = "Background: Mast cell activation syndrome (MCAS) describes patients with episodes of mast cell mediator release, with negative bone marrow biopsy results, and the failure to meet the criteria for systemic mastocytosis. Objective: Identify elevation of mast cell mediators of patients with MCAS. Methods: We performed a retrospective study of 25 patients with MCAS who were evaluated at Mayo Clinic from 2006 to2012. Patients were reviewed for MCAS symptoms and mast cell mediators, including serum tryptase and 24-hour urine N-methyl histamine (N-MH) and 11β-prostaglandin-F2α (11β-PGF2α). The study was approved by the institutional review board. Results: Urinary 11β-PGF2α was the most frequently elevated product in MCAS of our 25-patient cohort. Flushing and pruritus had the greatest correlation with elevation of 24-hour urine 11β-PGF2α value at baseline. The serum tryptase level was elevated in 10 patients, whereas the N-MH level was elevated with 2 patients. Eight of 9 patients with MCAS and with elevated 24-hour urine 11β-PGF2α who underwent aspirin therapy and follow-up urinary studies had normalization of this mediator (1patient did not have a follow-up urine study). Six of these 9patients with MCAS who underwent aspirin therapy had symptomatic improvement. Conclusion: We recommend measurement of 24-hour urine 11β-PGF2α and serum tryptase levels of patients with symptoms suggestive of MCAS. Measurement of 24-hour urine 11β-PGF2α and serum tryptase levels can help avoid misdiagnosis and overinterpretation of MCAS symptoms in clinical practice. Given that an elevation of 24-hour urine N-MH level was found only in 2 patients, measurement of this mediator may be less helpful in diagnosing MCAS. We recommend aspirin therapy for patients with MCAS and with elevated 24-hour urine 11β-PGF2α levels.",
keywords = "11β-Prostaglandin-F2α, Mast cell, Mast cell activation syndrome, Tryptase",
author = "Anupama Ravi and Joseph Butterfield and Weiler, {Catherine R.}",
year = "2014",
doi = "10.1016/j.jaip.2014.06.011",
language = "English (US)",
volume = "2",
pages = "775--778",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Mast Cell Activation Syndrome

T2 - Improved Identification byCombined Determinations of Serum Tryptase and 24-Hour Urine 11β-Prostaglandin2α

AU - Ravi, Anupama

AU - Butterfield, Joseph

AU - Weiler, Catherine R.

PY - 2014

Y1 - 2014

N2 - Background: Mast cell activation syndrome (MCAS) describes patients with episodes of mast cell mediator release, with negative bone marrow biopsy results, and the failure to meet the criteria for systemic mastocytosis. Objective: Identify elevation of mast cell mediators of patients with MCAS. Methods: We performed a retrospective study of 25 patients with MCAS who were evaluated at Mayo Clinic from 2006 to2012. Patients were reviewed for MCAS symptoms and mast cell mediators, including serum tryptase and 24-hour urine N-methyl histamine (N-MH) and 11β-prostaglandin-F2α (11β-PGF2α). The study was approved by the institutional review board. Results: Urinary 11β-PGF2α was the most frequently elevated product in MCAS of our 25-patient cohort. Flushing and pruritus had the greatest correlation with elevation of 24-hour urine 11β-PGF2α value at baseline. The serum tryptase level was elevated in 10 patients, whereas the N-MH level was elevated with 2 patients. Eight of 9 patients with MCAS and with elevated 24-hour urine 11β-PGF2α who underwent aspirin therapy and follow-up urinary studies had normalization of this mediator (1patient did not have a follow-up urine study). Six of these 9patients with MCAS who underwent aspirin therapy had symptomatic improvement. Conclusion: We recommend measurement of 24-hour urine 11β-PGF2α and serum tryptase levels of patients with symptoms suggestive of MCAS. Measurement of 24-hour urine 11β-PGF2α and serum tryptase levels can help avoid misdiagnosis and overinterpretation of MCAS symptoms in clinical practice. Given that an elevation of 24-hour urine N-MH level was found only in 2 patients, measurement of this mediator may be less helpful in diagnosing MCAS. We recommend aspirin therapy for patients with MCAS and with elevated 24-hour urine 11β-PGF2α levels.

AB - Background: Mast cell activation syndrome (MCAS) describes patients with episodes of mast cell mediator release, with negative bone marrow biopsy results, and the failure to meet the criteria for systemic mastocytosis. Objective: Identify elevation of mast cell mediators of patients with MCAS. Methods: We performed a retrospective study of 25 patients with MCAS who were evaluated at Mayo Clinic from 2006 to2012. Patients were reviewed for MCAS symptoms and mast cell mediators, including serum tryptase and 24-hour urine N-methyl histamine (N-MH) and 11β-prostaglandin-F2α (11β-PGF2α). The study was approved by the institutional review board. Results: Urinary 11β-PGF2α was the most frequently elevated product in MCAS of our 25-patient cohort. Flushing and pruritus had the greatest correlation with elevation of 24-hour urine 11β-PGF2α value at baseline. The serum tryptase level was elevated in 10 patients, whereas the N-MH level was elevated with 2 patients. Eight of 9 patients with MCAS and with elevated 24-hour urine 11β-PGF2α who underwent aspirin therapy and follow-up urinary studies had normalization of this mediator (1patient did not have a follow-up urine study). Six of these 9patients with MCAS who underwent aspirin therapy had symptomatic improvement. Conclusion: We recommend measurement of 24-hour urine 11β-PGF2α and serum tryptase levels of patients with symptoms suggestive of MCAS. Measurement of 24-hour urine 11β-PGF2α and serum tryptase levels can help avoid misdiagnosis and overinterpretation of MCAS symptoms in clinical practice. Given that an elevation of 24-hour urine N-MH level was found only in 2 patients, measurement of this mediator may be less helpful in diagnosing MCAS. We recommend aspirin therapy for patients with MCAS and with elevated 24-hour urine 11β-PGF2α levels.

KW - 11β-Prostaglandin-F2α

KW - Mast cell

KW - Mast cell activation syndrome

KW - Tryptase

UR - http://www.scopus.com/inward/record.url?scp=84923135398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923135398&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2014.06.011

DO - 10.1016/j.jaip.2014.06.011

M3 - Article

C2 - 25439370

AN - SCOPUS:84923135398

VL - 2

SP - 775

EP - 778

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 6

ER -